Participant Perspectives: Integration and Aftercare in Psychedelic Trials

PARTICIPANT PERSPECTIVES: INTEGRATION AND AFTERCARE IN PSYCHEDELIC TRIALS

🗣Leonie Schneider and Ian Roullier, former psilocybin and DMT trial participants plus Hadas Aglamaz and Pedram Dara, two former MDMA therapy participants.

⏰Thu 15th June, 8PM CEST (7PM GMT, 2PM EST, 11AM PST)

📍Online (OPEN Community Platform)

Come join us for a fascinating panel discussion on the critical role of integration and aftercare in psychedelic trials, featuring former psilocybin and DMT trial participants Leonie Schneider and Ian Roullier, alongside former MDMA therapy participants Hadas Aglamaz and Pedram Dara. Our panelists will provide valuable first-hand insights into their experiences undergoing psychedelic therapy as trial participants, discussing the often-overlooked issue of inadequate integration and aftercare support and exploring potential solutions to improve the process.

Beyond sharing their personal experiences, the panelists will delve into the profound psychological and emotional effects of psychedelic therapies and how these experiences have impacted their lives. This event promises to be of great interest to researchers, mental health professionals, and anyone keen to learn more about the rapidly evolving field of psychedelic therapy, particularly in the context of clinical trials.

WHAT'S UNIQUE ABOUT THIS EVENT?

Attending this online event is an interactive experience, unlike watching a lecture on YouTube or a webinar. You'll have the chance to connect with the speakers directly and ask questions, allowing you to explore the topic in greater depth.

READY TO ATTEND?

ATTEND FOR FREE AS A MEMBER

Unlock access to this and all exclusive events with leading psychedelic experts and engage in real time through the OPEN Membership Programme. Plus, enjoy a community space, a content library, discounts, and more.

ATTEND WITH A SMALL DONATION

Not ready to become a member? You can attend this event through a small one-time donation and get a free trial of the OPEN Membership Programme while supporting the nonprofit mission of the OPEN Foundation.

Really want to attend but can’t afford a donation? Apply for a one-time free access here.

ABOUT THE SPEAKERS

Leonie Schneider participated in the Psilocybin for Depression clinical trial at Imperial College (2019) and Small Pharma’s DMT for Depression trial (2022).

Ian Roullier particiapted in both the Imperial College London psilocybin for depression pilot study (2015) and the COMPASS Pathways psilocybin trial (2019).

Hadas Aglamaz participated in open-label phase 2 trials of MDMA for PTSD in Israel (2015).

Pedram Dara participated in open-label phase 2 trials of MDMA for PTSD in Canada (2019).

The panel discussion will be moderated by an expert in the field of psychedelic research, who will provide insights into the current state of integration and aftercare in psychedelic trials. The event will be an excellent opportunity to learn from the participants themselves, understand their unique perspectives, and explore ways to improve the integration and aftercare process for future trials.

READY TO ATTEND?

ATTEND FOR FREE AS A MEMBER

ATTEND WITH A SMALL DONATION

Really want to attend but can’t afford a donation? Apply for a one-time free access here.

ALREADY A MEMBER?

To access the OPEN Community Platform, click the button below. The platform not only live streams all events, but also provides direct access to event recordings.